MicroRNA-7 as a Potential Biomarker for Prognosis in Pancreatic Cancer.
Journal
Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
09
2019
revised:
21
04
2020
accepted:
13
05
2020
entrez:
23
6
2020
pubmed:
23
6
2020
medline:
15
4
2021
Statut:
epublish
Résumé
MicroRNAs play critical roles in tumor progression. Our recent study has indicated that microRNA-7 (miR-7) impairs autophagy-derived pools of glucose to suppress the glycolysis in pancreatic cancer progression. However, the roles of miR-7 in clinical significance and chemoresistance of pancreatic cancer remain unexplored. The aim of this study was to assess the expression of miR-7 in patients with pancreatic cancer and to evaluate the possibility of its usage as a prognostic molecular biomarker. MicroRNA array-based quantification analysis of 372 miRNAs was compared in serum between pancreatic cancer and healthy individuals, gemcitabine-sensitive and gemcitabine-resistance patients. We identified miR-7 showed the potential predictive power for gemcitabine-sensitive patients with pancreatic cancer. Then, the results were validated in pancreatic tissue microarray and The Cancer Genome Atlas (TCGA) dataset, demonstrating that lower miR-7 expression was correlated with more advanced tumor stages and worse prognosis in pancreatic cancer. The Cox proportional-hazards model analysis identified miR-7 to be an independent variable for prediction of the survival. Furthermore, the mechanistic exploration suggested the clinical significance of miR-7 involved its interference effect on autophagy and glycolysis in pancreatic cancer using pancreatic cancer tissue microarrays and TCGA data. Therefore, the results of the present study provide evidences that low microRNA-7 expression may contribute to tumor progression and poor prognosis in pancreatic cancer.
Identifiants
pubmed: 32566037
doi: 10.1155/2020/2782101
pmc: PMC7288197
doi:
Substances chimiques
Antimetabolites, Antineoplastic
0
Biomarkers, Tumor
0
Circulating MicroRNA
0
MIRN7 microRNA, human
0
MicroRNAs
0
Deoxycytidine
0W860991D6
Gemcitabine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2782101Informations de copyright
Copyright © 2020 Zhi-qiang Ye et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Mol Cancer. 2015 Oct 05;14:177
pubmed: 26438046
Int J Cancer. 2015 Jan 1;136(1):152-61
pubmed: 23456911
Cancer Res. 2009 Jul 15;69(14):5820-8
pubmed: 19584296
Mol Ther Nucleic Acids. 2018 Dec 7;13:121-132
pubmed: 30290304
Carcinogenesis. 2014 Oct;35(10):2203-13
pubmed: 24879635
Cancer Lett. 2014 Jun 1;347(2):167-74
pubmed: 24561061
Biochem Biophys Res Commun. 2018 Mar 18;497(4):963-970
pubmed: 29408481
Clin Cancer Res. 2017 Jul 15;23(14):3918-3928
pubmed: 28174233
PLoS One. 2015 Dec 28;10(12):e0144969
pubmed: 26709920
Mol Cancer. 2015 Oct 12;14:179
pubmed: 26458814
Cancer Lett. 2017 Aug 1;400:69-78
pubmed: 28450156
J Cell Biol. 2015 Aug 17;210(4):613-27
pubmed: 26261179
Tumour Biol. 2014 Jul;35(7):7105-13
pubmed: 24760272
N Engl J Med. 2013 Feb 14;368(7):651-62
pubmed: 23406030
J Clin Oncol. 1997 Jun;15(6):2403-13
pubmed: 9196156
Thyroid. 2012 Mar;22(3):285-91
pubmed: 22304369
Lancet. 2016 Jul 2;388(10039):73-85
pubmed: 26830752
Cancer Lett. 2012 Jul 28;320(2):138-49
pubmed: 22425961
Curr Biol. 2014 Aug 18;24(16):R762-76
pubmed: 25137592
Expert Opin Ther Targets. 2015 Mar;19(3):415-26
pubmed: 25434362
Oncogene. 2013 Mar 14;32(11):1363-72
pubmed: 22614005
Hepatology. 2012 Jun;55(6):1852-62
pubmed: 22234835
Cancer Res. 2013 Feb 15;73(4):1434-44
pubmed: 23384942
Cancer Lett. 2016 Jan 28;370(2):332-44
pubmed: 26586345
Oncogene. 2013 Oct 17;32(42):5078-88
pubmed: 23208495